Biocon Limited has informed the Exchange regarding a press release dated July 07, 2025, titled "Biocon Biologics Receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars".
Press Release Jul 07 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from Biocon
- Press Release Jul 03 2025
- Press Release Jun 30 2025
- Press Release Jun 27 2025
- Biocon Biologics Receives Health Canada Approval for Yesafili™ (aflibercept); First Global Launch Scheduled for July 2025
- Press Release Jun 24 2025
Later from Biocon
- Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States
- Press Release Jul 16 2025
- Press Release Jul 23 2025
- Press Release Jul 28 2025
- Press Release Aug 07 2025
Follow Biocon into a list and get an email when it puts out news.
Follow Biocon